* Newstin.com is for sale! * After achieving our strategic milestone, we are offering for sale: Newstin.com and all 14 related domains featuring 1 million unique visitors per month + continuously updated news database of 37 million articles in 12 world languages from 166,000 global and weighted sources + 2.1 billion metadata * To seize this unique chance, contact invest@newstin.com. * Newstin.com is for sale! *

Cell Genesys

Biotech Stocks: Cell Genesys, Amylin lead drug stocks lower

marketwatch.com
Aug 27, 2008 61 related
        

By Val Brickates Kennedy, MarketWatch BOSTON (MarketWatch) -- Drug stocks dipped in early action Wednesday as shares of Cell Genesys dived on news that it was discontinuing a key clinical trial for its prostate cancer...

add comment

Cell Genesys to Present at the 28th Annual Canaccord Adams Global Growth Conference (Business Wire)

yahoo.com
Aug 6, 2008
        

SOUTH SAN FRANCISCO, Calif.----Cell Genesys, Inc. today announced that Sharon E. Tetlow, senior vice president and chief financial officer of Cell Genesys, will present a company update at the 28th Annual Canaccord Adams Global...

add comment

Cell Genesys loss grows to $2.8M (at bizjournals.com)

yahoo.com
Aug 4, 2008 1 related
        

lost $2.8 million in the second quarter ended June 30. A year ago in the second quarter the South San Francisco company (NASDAQ: CEGE) lost $1.9 million. The company reported revenue of $16.6 million during the quarter, all of...

add comment
                   
genengnews.com: Genetic Engineering genengnews.com

Cell Genesys loss widens in the second quarter

ibtimes.com
Aug 2, 2008 10 related
        

SOUTH SAN FRANCISCO, Calif. - Biotech drug developer Cell Genesys Inc. reported Friday its loss widened in the second quarter, despite a major revenue infusion from a collaboration with Takeda Pharmaceuticals. For the period...

add comment
                   

InPlay: Oshkosh Truck beats by $0.14, beats on revs; guides Q4 EPS below consensus; guides FY08...

yahoo.com
Aug 2, 2008 5 related
        

4:52PM Continental Airlines reports July 2008 operational performance 13.04 -0.69 : Co reported a July consolidated (mainline plus regional) load factor of 84.2%, 2.2 points below the July 2007 consolidated load factor, and a...

add comment

Q2 2008 Cell Genesys Earnings Release - After Market Close (CCBN)

yahoo.com
Aug 2, 2008 131 related
        

Analyst opinion data (recommendation summary, price targets, coverage list) are provided by Thomson Financial Network, based solely upon research information provided by third party analysts. Yahoo! has not reviewed, and in no...

add comment
                   

Russia Approves an Unproven Treatment (at Motley Fool)

yahoo.com
Jul 31, 2008 3 related
        

By Brian Orelli April 9, 2008 Comments (0) Investors in Dendreon (Nasdaq: DNDN) and Cell Genesys (Nasdaq: CEGE) who were hoping their companies would have the world's first approved cancer vaccine are going to have to duke it...

add comment
                   

Cancer Vaccine Contenders Lurk Among the Casualties

tmcnet.com
Jul 28, 2008 8 related
        

Between the negative Phase III news on Oxford BioMedica plc's TroVax and the positive Phase III news on Biovest International Inc.'s BiovaxID, it's been a big month for cancer vaccines. But despite all the failures and amid all...

add comment
                   

Cell Genesys' Final Results From Phase 2 Clinical Trial of GVAX Immunotherapy Published

tmcnet.com
Jul 27, 2008 4 related
        

Cell Genesys announced the publication of final data from the second of two Phase 2 clinical trials (G-0010) of GVAX immunotherapy for prostate cancer in the online issue of Cancer, a peer-reviewed publication of the American...

add comment
                   
genengnews.com: Genetic Engineering genengnews.com

Final Results From Phase 2 Clinical Trial of GVAX Immunotherapy for Prostate Cancer Published in...

genengnews.com
Jul 22, 2008 107 related
        

News source: Business Wire Cell Genesys, Inc. announced today the publication of final data from the second of two Phase 2 clinical trials (G-0010) of GVAX immunotherapy for prostate cancer in the online issue of Cancer, a...

comments (1)